摘要:
A monoclonal antibody or an antigen binding fragment thereof that (a) specifically binds to ±v²6 but does not bind other av integrins; and (b) does not inhibit the binding of ²6 to latency associated peptide (LAP) with an IC50 value lower than that of 10D5. Said monoclonal antibody, wherein the antibody comprises a) the same heavy and light chain polypeptide sequences as an antibody produced by hybridoma 6. 2A1 (ATCC accession number PTA-3896) or b) the same heavy and light chain polypeptide sequences as an antibody produced by hybridoma 6.2E5 (ATCC accession number PTA-3897). The disclosure also relates to uses of same and to compositions comprising same.
摘要:
The present invention relates to biomarkers for use in determining the sensitivity of patients to therapy with αvβ6 integrin inhibition or therapy with TGF-β pathway inhibitors. The biomarker profiles disclosed herein provide individualized gene and protein profiles which will aid in treating diseases and disorders which are amenable to treatment with therapies designed against αvβ6-integrin and/or TGF-β pathway inhibitors.
摘要:
Herein are provided, inter alia, methods for treating fibrosis by pharmacological modulation of the alphavbeta 1 integrin. Compositions small molecule inhibitors are presented as one route to test the role of the alphavbeta1, integrin in tissue fibrosis. Further, assays to test the inhibition of alphavbeta 1, in myofibrotic cells and the subsequent inhibition of TGF-beta by alphavbeta1 specific inhibitors are also disclosed.
摘要:
Methods and compositions for regulating fatty acid uptake and/or decreasing gastric motility in an animal are provided. The method comprises administering an antagonist of integrin αv&bgr;3 or αv&bgr;5 to an animal in an amount sufficient to reduce fatty acid uptake in the animal, thereby reducing fatty acid uptake in the animal. In some embodiments, the antagonist is an antibody. Also provided is a method of increasing fatty acid uptake and/or gastric motility in an animal.
摘要:
The present invention provides compositions and methods for treating and preventing disease associated with αvβ5 integrin by blocking binding to αvβ5 integrin. In particular, antibodies specific for αvβ5 integrin are useful for preventing, treating, and reversing sepsis.
摘要:
The present invention relates to methods of asthma treatment and prevention using αvβ6 antagonists, such as αvβ6-binding antibodies. In particular, the invention relates to the discovery of a correlation between reduced expression of αvβ6 and the protection from the increase in airway sensitivity seen in chronic allergen-challenged mice. This protection is associated with protection from the usual allergen-induced increase in airway epithelial mast cells.